ArticleRSC medicinal chemistry2020
G-Protein biased opioid agonists: 3-hydroxy-
Open access · greenAbstract read
In one paragraph
Article in RSC medicinal chemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.0field-weighted citation impact, top 28% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 14 citations in OpenAlex.
- Effects of repeated treatment with opioids that vary in mu opioid receptor efficacy on pain-depressed locomotor behavior in mice.Psychopharmacology · 2026Article
- Transformation of a Potent C9-Substituted Phenylmorphan into MOR Partial Agonists with Improvement of Metabolic Stability: An In Vitro, In Vivo, and In Silico Study.ACS chemical neuroscience · 2025Article
- Low-Efficacy Mu Opioid Agonists as Candidate Analgesics: Effects of Novel C-9 Substituted Phenylmorphans on Pain-Depressed Behavior in Mice.The Journal of pharmacology and experimental therapeutics · 2024Article
- Functional Activity of Enantiomeric Oximes and Diastereomeric Amines and Cyano Substituents at C9 in 3-Hydroxy-Molecules (Basel, Switzerland) · 2024Article
- Potent MOR Agonists from 2'-Hydroxy-5,9-dimethyl-Molecules (Basel, Switzerland) · 2023Article
- Role of efficacy as a determinant of locomotor activation by mu-opioid receptor (MOR) ligands in female and male mice. II. Effects of novel MOR-selective phenylmorphans with high-to-low MOR efficacy.Pharmacology research & perspectives · 2023Article
- A MOR Antagonist with High Potency and Antagonist Efficacy among Diastereomeric C9-Alkyl-SubstitutedMolecules (Basel, Switzerland) · 2023Article
- Discovery of a Potent Highly Biased MOR Partial Agonist among Diastereomeric C9-Hydroxyalkyl-5-phenylmorphans.Molecules (Basel, Switzerland) · 2023Article
- A Journey through Diastereomeric Space: The Design, Synthesis, In Vitro and In Vivo Pharmacological Activity, and Molecular Modeling of Novel Potent Diastereomeric MOR Agonists and Antagonists.Molecules (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 5 institutions in 3 countries.
Eugene S GutmanDrug Design and Synthesis Section , Molecular Targets and Medications Discovery Branch , Intramural Research Program , National Institute on Drug Abuse , National Institute on Alcohol Abuse and Alcoholism , National Institutes of Health , Department of Health and Human Services , 9800 Medical Center Drive , Bethesda , MD 20892-3373 , USA . Email: arthurj@nida.nih.gov ; Email: kennerr@mail.nih.gov ; ; Tel: +1 301 240 5216 ; Tel: +1 301 217 5200.
Eric BowDrug Design and Synthesis Section , Molecular Targets and Medications Discovery Branch , Intramural Research Program , National Institute on Drug Abuse , National Institute on Alcohol Abuse and Alcoholism , National Institutes of Health , Department of Health and Human Services , 9800 Medical Center Drive , Bethesda , MD 20892-3373 , USA . Email: arthurj@nida.nih.gov ; Email: kennerr@mail.nih.gov ; ; Tel: +1 301 240 5216 ; Tel: +1 301 217 5200.
Fuying LiDrug Design and Synthesis Section , Molecular Targets and Medications Discovery Branch , Intramural Research Program , National Institute on Drug Abuse , National Institute on Alcohol Abuse and Alcoholism , National Institutes of Health , Department of Health and Human Services , 9800 Medical Center Drive , Bethesda , MD 20892-3373 , USA . Email: arthurj@nida.nih.gov ; Email: kennerr@mail.nih.gov ; ; Tel: +1 301 240 5216 ; Tel: +1 301 217 5200.
Agnieszka SulimaDrug Design and Synthesis Section , Molecular Targets and Medications Discovery Branch , Intramural Research Program , National Institute on Drug Abuse , National Institute on Alcohol Abuse and Alcoholism , National Institutes of Health , Department of Health and Human Services , 9800 Medical Center Drive , Bethesda , MD 20892-3373 , USA . Email: arthurj@nida.nih.gov ; Email: kennerr@mail.nih.gov ; ; Tel: +1 301 240 5216 ; Tel: +1 301 217 5200.
Sophia KaskaDepartment of Pharmaceutical Sciences , College of Pharmacy , University of Kentucky , 789 S. Limestone Street , Lexington , Kentucky 40536 , USA.
Rachel CrowleyDepartment of Medicinal Chemistry , School of Pharmacy , University of Kansas , 1251 Wescoe Hall Drive, 4070 Malott , Lawrence , Kansas 66045 , USA.
Thomas E PrisinzanoDepartment of Pharmaceutical Sciences , College of Pharmacy , University of Kentucky , 789 S. Limestone Street , Lexington , Kentucky 40536 , USA.ORCID 0000-0002-0649-8052
Yong-Sok LeeCenter for Molecular Modeling, Center for Information Technology , National Institutes of Health , Department of Health and Human Services , 9800 Medical Center Drive , Bethesda , MD 20892-5624 , USA.
Sergio A HassanCenter for Molecular Modeling, Center for Information Technology , National Institutes of Health , Department of Health and Human Services , 9800 Medical Center Drive , Bethesda , MD 20892-5624 , USA.ORCID 0000-0003-3319-078X
Gregory H ImlerCenter for Biomolecular Science and Engineering , Naval Research Laboratory , Washington DC , 20375-0001 , USA.
Jeffrey R DeschampsCenter for Biomolecular Science and Engineering , Naval Research Laboratory , Washington DC , 20375-0001 , USA.
Arthur E JacobsonDrug Design and Synthesis Section , Molecular Targets and Medications Discovery Branch , Intramural Research Program , National Institute on Drug Abuse , National Institute on Alcohol Abuse and Alcoholism , National Institutes of Health , Department of Health and Human Services , 9800 Medical Center Drive , Bethesda , MD 20892-3373 , USA . Email: arthurj@nida.nih.gov ; Email: kennerr@mail.nih.gov ; ; Tel: +1 301 240 5216 ; Tel: +1 301 217 5200.ORCID 0000-0002-0011-8354
Kenner C RiceDrug Design and Synthesis Section , Molecular Targets and Medications Discovery Branch , Intramural Research Program , National Institute on Drug Abuse , National Institute on Alcohol Abuse and Alcoholism , National Institutes of Health , Department of Health and Human Services , 9800 Medical Center Drive , Bethesda , MD 20892-3373 , USA . Email: arthurj@nida.nih.gov ; Email: kennerr@mail.nih.gov ; ; Tel: +1 301 240 5216 ; Tel: +1 301 217 5200.
National Institute on Drug Abuse · USNational Institutes of Health · USUnited States Naval Research Laboratory · USUniversity of Kentucky · USUniversity of Kansas · US
Funding
Investigation of Neoclerodanes as Novel Opioid LigandsR01DA018151 · NIDA · UNIVERSITY OF KENTUCKY · PI PRISINZANO, THOMAS EDWARD · 2005 to 2020
$5.7MTRAINING GRANT IN DYNAMIC ASPECTS OF CHEMICAL BIOLOGYT32GM008545 · NIGMS · UNIVERSITY OF KANSAS LAWRENCE · PI LAMB, AUDREY L · 1994 to 2019
$4.9MNIDA NIH HHS R01 DA018151NIGMS NIH HHS T32 GM008545
Abstract
A series of compounds have been synthesized with a variety of substituents based on a three-carbon chain at the C9-position of 3-hydroxy-
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.